Abstract
For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimers disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinsons disease, and Huntingtons disease. Despite these demonstrated and prospective therapeutic benefits, lithiums mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Most recent publications discussing the medical application of lithium have converged on GSK-3, so this article reviews data and discussions regarding the roles and interactions of GSK-3 with other proteins and its proposed role in the pathogenesis of Alzheimers disease.
Keywords: Alzheimer disease, neuronal apoptosis, Tau Phosphorylation, Presenilin- 1, Amyloid beta
Current Alzheimer Research
Title: Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Volume: 4 Issue: 1
Author(s): Saeed Yadranji Aghdam and Steven W. Barger
Affiliation:
Keywords: Alzheimer disease, neuronal apoptosis, Tau Phosphorylation, Presenilin- 1, Amyloid beta
Abstract: For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimers disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinsons disease, and Huntingtons disease. Despite these demonstrated and prospective therapeutic benefits, lithiums mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Most recent publications discussing the medical application of lithium have converged on GSK-3, so this article reviews data and discussions regarding the roles and interactions of GSK-3 with other proteins and its proposed role in the pathogenesis of Alzheimers disease.
Export Options
About this article
Cite this article as:
Yadranji Aghdam Saeed and Barger W. Steven, Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium, Current Alzheimer Research 2007; 4 (1) . https://dx.doi.org/10.2174/156720507779939832
DOI https://dx.doi.org/10.2174/156720507779939832 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Alzheimer Disease: What Role for Leptin and Insulin?
Central Nervous System Agents in Medicinal Chemistry Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Tumor Hypoxia as a Modifier of DNA Strand Break and Cross-Link Repair
Current Molecular Medicine 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) Novel Aspects of Neuronal Differentiation In Vitro and Monitoring with Advanced Biosensor Tools
Current Medicinal Chemistry Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Editorial (Hot Topic: Innovative Approaches for the Management of Pediatric Malignancies)
Current Medicinal Chemistry Effects of 900MHz Mobile Phone Radiation on Human Thyroid Hormone Levels
Recent Patents on Biomarkers Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry